Cancer Family
Connective and Soft Tissue Neoplasm
CI-CAN-00000010Explore in graph →
Non-malignant849 active trials17 approved drugs339 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000010Explore in graph →
Clinical trials
3,878 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673861 | Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients(CURTAIN) | recruiting | N/A | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 29, 2026 |
| clinicaltrials |
| NCT04488822 | A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT(PLX3397) | active not recruiting | Phase 3 | 40 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Jun 26, 2026 | clinicaltrials |
| NCT04673942 | A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors(BETA-PRIME) | active not recruiting | Phase 2 | 140 | EpicentRx, Inc.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03069469 | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | active not recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jun 25, 2026 | clinicaltrials |
| NCT06126588 | Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial(ELUMEN) | recruiting | Phase 2 | 28 | Central Hospital, Nancy, FranceOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06459141 | The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery | recruiting | N/A | 150 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05653388 | Metastatic Leiomyosarcoma Biomarker Protocol | recruiting | — | 200 | University of Michigan Rogel Cancer CenterOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT05676099 | TSC Biosample Repository and Natural History Database | recruiting | — | 5,000 | National Tuberous Sclerosis AssociationOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT07664956 | Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy | not yet recruiting | Phase 4 | 36 | Christiana Care Health ServicesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07665177 | Abrupt Discontinuation Versus Gradual Tapering of Propranolol in Infantile Hemangioma(PROIHSTOP) | not yet recruiting | Phase 4 | 110 | West China HospitalOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03818412 | Circulating Tumor DNA in Soft Tissue Sarcoma | recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03896620 | Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma | active not recruiting | — | 45 | Medical College of WisconsinOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04668300 | Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma(DOSa) | active not recruiting | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05180695 | HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas(AMPHISARC) | active not recruiting | Phase 1 / Phase 2 | 47 | Centre Leon BerardOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05526417 | Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherapy and Surgery for Soft Tissue Sarcoma | recruiting | N/A | 33 | Mayo ClinicOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06416085 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer | active not recruiting | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07650656 | Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial | recruiting | Phase 2 | 22 | City of Hope Medical CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658768 | Pilot Study of TumorGlow for Intraoperative Molecular Imaging of Sarcoma Metastases to the Lungs in Pediatric Patients(TumorGlow) | not yet recruiting | Early Phase 1 | 20 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07661342 | DEPART Study at Yale(Dupuytren's) | not yet recruiting | Phase 3 | 158 | Yale UniversityOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04616248 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | active not recruiting | Phase 1 | 14 | University of Southern CaliforniaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06088290 | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)(SaLuDo) | active not recruiting | Phase 3 | 469 | PharmaMarINDUSTRY | 12 | Jun 18, 2026 | clinicaltrials |
| NCT06571734 | XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma | recruiting | Phase 2 | 73 | Northwestern UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07502885 | Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients | recruiting | — | 300 | St. Jude Children's Research HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656909 | Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP | recruiting | Phase 2 / Phase 3 | 76 | Yi JiOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT00840047 | Methionine PET/CT Studies In Patients With Cancer | active not recruiting | Phase 2 | 503 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01346124 | High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull | active not recruiting | N/A | 64 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01871766 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | active not recruiting | Phase 2 | 115 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03050268 | Familial Investigations of Childhood Cancer Predisposition(SJFAMILY) | recruiting | — | 1,500 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT07654647 | Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.(3DFACE) | recruiting | N/A | 30 | Latakia UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04534127 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia | recruiting | N/A | 56 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT07646080 | Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans | not yet recruiting | Phase 2 | 20 | Yanjie Zhang, MDOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650110 | Biological Collection of the Rare Diseases of the Brain and Eye Vessels Cohort - 2(B-MRVC2) | not yet recruiting | N/A | 600 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07650838 | OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) | not yet recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT06023641 | Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease | recruiting | Phase 2 | 135 | St. Jude Children's Research HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06326190 | 177Lu-DOTATATE for Recurrent Meningioma(LUMEN-1) | recruiting | Phase 2 | 136 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jun 15, 2026 | clinicaltrials |
| NCT06749366 | Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing | recruiting | — | 100 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06967961 | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers(DP-PAN-CANCER) | recruiting | N/A | 450 | Institut Claudius RegaudOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647068 | Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors | not yet recruiting | Phase 2 | 59 | Joal BeaneOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648069 | Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma | recruiting | Phase 1 | 16 | Sun Yat-sen UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04589741 | Toripalimab Combined With CAV/IE Regimen | recruiting | Phase 2 | 134 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07640425 | Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture | recruiting | Phase 1 / Phase 2 | 60 | CONNEXTINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04771520 | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05106777 | Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma | active not recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 29, 2026source: clinicaltrials